Idiopathic erythrocytosis (IE) is a heterogeneous collection of rare haematologic disorders which can be either sporadic or familial in origin [1] . An erythrocytosis occurs when there is an increased red cell mass and an elevated haematocrit. IE is distinct from polycythaemia vera (PV) as the red cell hyperplasia present in IE is not accompanied by elevations in the megakaryocytic or granulocytic lineages and PV is characterized by low serum erythropoietin (Epo) levels, whereas IE is associated with a wide range of Epo levels. IE can be divided into 2 main groups. The first group consists of those with a low EPO level suggesting an unidentified molecular defect possibly involving components of the Epo signal transduction pathway [2] . The second group is comprised of those with an inappropriately normal or raised EPO level which suggests a secondary unidentified cause possibly affecting the oxygen sensing pathway. These patients are rarely observed in clinical practice, and little is known regarding their clinical characteristics, natural history, and best management.
Recently, novel frameshift mutations in exon 9 of the calreticulin (CALR) gene were found in patients with JAK2 or MPL unmutated primary myelofibrosis and essential thrombocythemia (ET) [3, 4] . Even though mutations of CALR have been reported in significant numbers in myeloproliferative neoplasm (MPN) it was initially thought that CALR mutations did not occur in PV. However, in 2014 two JAK2-negative PV patients were described that harboured CALR mutations (52-bp deletion) [5] with further cases described in other studies [6] .
The aims of this study were to assess the prevalence of CALR mutations in (1) a well characterized cohort of IE patients with low serum Epo levels and (2) a broad cohort of query MPN cases referred for molecular genetic investigation.
DOI: 10.1159/000489006
Initially we studied 79 patients with IE. Thirty-eight were enrolled from a UK cohort and 41 from a French cohort.
Ethical approval was granted by the local review committees and informed consent was collected according to the Helsinki Declaration.
All of the patients had low to normal serum EPO levels ( Table 1 ) and none of them carried JAK2V617F or JAK2 exon 12 mutations as determined by allele-specific PCR. Clinical and laboratory details of the patients are shown in Table 1 . The procedures followed were in accordance with the Declaration of Helsinki and all patients gave informed written consent. CALR exon 9 mutations were screened by fragment length analysis according to Klampfl et al. [3] .
The patients were mostly males in both of the groups, with a higher frequency in the French cohort. Patients in both cohorts had similar characteristics (Table 1) . No CALR mutations were detected in any of the 79 IE patients included in this study with low to normal EPO levels.
To further explore the possibility of CALR mutations in PV, we audited samples referred for MPN panel analysis at the Wessex Regional Genetics Laboratory (WRGL) in Salisbury [7] . Since October 2016, all query MPN referrals to the WRGL have been tested using an ampliconbased next-generation sequencing approach for JAK2 V617F, JAK2 exon 12, MPL exon 10, and CALR exon 9 mutations irrespectively of their phenotype. Of 2,306 referrals, 137 (5.9%) tested positive for CALR +1 frameshift mutations. None of the 659 referrals that specified an erythroid phenotype PV (PV, high haematocrit, or high haemoglobin) tested positive for CALR mutations.
In previous studies 4 CALR mutations have been identified in so-called JAK2-negative PV in patients more accurately described as JAK2-negative unexplained erythrocytosis. In the first study only 2 patients were studied [5] . Both cases were JAK2-negative PV and the CALR mutation was a 52-bp deletion, commonly termed a type 1 mutation. Of note, both patients had thrombocytosis in addition to erythrocytosis. In the second study a large cohort of 578 patients was examined [6] . Of the 2 patients with CALR mutations one was subsequently considered to have essential thrombocythemia with a slightly increased red cell mass and the other was considered to have IE. Both cases harboured the 52-bp deletion. Of interest, in the patient with IE the CALR mutation was detected with a low allele burden of approximately 5%.
The underlying defect in cases with unexplained erythrocytosis presents a clinical conundrum. Our findings indicate that CALR mutations are absent in a cohort of 79 patients with IE and also in a large, broad real-life cohort of patients with an erythroid phenotype referred for MPN panel testing. We therefore consider that the screening of CALR mutations in this situation is not warranted as a stand-alone investigation.
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